SLC13A5 and metabolic dysfunction-associated steatotic liver disease: An increased expression of SLC13A5 in the liver has been observed in patients with obesity, NAFLD, and type 2 diabetes as well as in cultured primary hepatocytes treated with glucagon, BaP, or RIF.